4
Changes in Ownership
NEKTAR THERAPEUTICS Filed Acc 0001193125-26-061886
Chief R&D Officer sold 180 shares at $73.00 ($13,140)
From the SEC's structured data for this filing
Trades in this filing
Zalevsky Jonathan · Chief R&D Officer
Table I: Non-derivative
1 line| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2026-02-18 | Sale : show line 1 in the form | −180 | $73.00 | $13,140 | 21,174 | D |
| Open-market sales · 180 sh · avg $73.00 · $13,140 | ||||||
Loading xslF345X05/ownership.xml…